Preliminary results from HERKULES-1: a phase 1b/2, open-label, multicenter study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors. (October 2022) - Wang, J.; Johnson, M.; Barve, M.; Pelster, M.; Chen, X.; Li, Z.; Gordon, J.; Reiss, M.; Pai, S.; Falchook, G.; Tolcher, A.